Outcomes
SARS-COV-2 INFECTION, ADVERSE EVENTS, ADVERSE EFFECT, SECONDARY, ADVERSE EVENT
The primary endpoint analysis included all participants in both the treatment and control groups. The primary endpoint was to assess the efficacy of the intranasal spray A8G6 for post-exposure prophylaxis of COVID-19. In this study, we compared the COVID-19 incidence of the close contacts between the A8G6 treatment individuals and the blank-controlled individuals. We also compared the time from enrollment to SARS-CoV-2 infection between the two groups. The secondary efficacy analysis included the quantitative data of SARS-CoV-2 RNA (log10 copies per mL) at baseline of the positive COVID-19 and the time to conversion of SARS-CoV-2 RNA from positive to negative (viral clearance).Safety endpoints was adverse event types and the incidence rate of adverse events among all participants of the A8G6 treatment group during the study. An adverse effect was defined as any abnormal signs or symptoms and harmful results caused by the study drug.